428 related articles for article (PubMed ID: 26892465)
21. Rapamycin-induced autophagy plays a pro-survival role by enhancing up-regulation of intracellular ferritin expression in acute lymphoblastic leukemia.
Gong Y; Wu J; Yang R; Zhang L; Ma Z
Exp Oncol; 2020 Mar; 42(1):11-15. PubMed ID: 32231197
[TBL] [Abstract][Full Text] [Related]
22. Targeting the PI3K/Akt/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia and its therapeutic potential.
Neri LM; Cani A; Martelli AM; Simioni C; Junghanss C; Tabellini G; Ricci F; Tazzari PL; Pagliaro P; McCubrey JA; Capitani S
Leukemia; 2014 Apr; 28(4):739-48. PubMed ID: 23892718
[TBL] [Abstract][Full Text] [Related]
23. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
[TBL] [Abstract][Full Text] [Related]
24. Preclinical in vivo evaluation of rapamycin in human malignant peripheral nerve sheath explant xenograft.
Bhola P; Banerjee S; Mukherjee J; Balasubramanium A; Arun V; Karim Z; Burrell K; Croul S; Gutmann DH; Guha A
Int J Cancer; 2010 Jan; 126(2):563-71. PubMed ID: 19634141
[TBL] [Abstract][Full Text] [Related]
25. The mammalian target of rapamycin inhibitor RAD001 (everolimus) synergizes with chemotherapeutic agents, ionizing radiation and proteasome inhibitors in pre-B acute lymphocytic leukemia.
Saunders P; Cisterne A; Weiss J; Bradstock KF; Bendall LJ
Haematologica; 2011 Jan; 96(1):69-77. PubMed ID: 20952516
[TBL] [Abstract][Full Text] [Related]
26. The dual specificity PI3K/mTOR inhibitor PKI-587 displays efficacy against T-cell acute lymphoblastic leukemia (T-ALL).
Gazi M; Moharram SA; Marhäll A; Kazi JU
Cancer Lett; 2017 Apr; 392():9-16. PubMed ID: 28159681
[TBL] [Abstract][Full Text] [Related]
27. FAK mediates the activation of cardiac fibroblasts induced by mechanical stress through regulation of the mTOR complex.
Dalla Costa AP; Clemente CF; Carvalho HF; Carvalheira JB; Nadruz W; Franchini KG
Cardiovasc Res; 2010 Jun; 86(3):421-31. PubMed ID: 20038548
[TBL] [Abstract][Full Text] [Related]
28. Rapamycin sensitizes glucocorticoid resistant acute lymphoblastic leukemia CEM-C1 cells to dexamethasone induced apoptosis through both mTOR suppression and up-regulation and activation of glucocorticoid receptor.
Guo X; Zhou CY; Li Q; Gao J; Zhu YP; Gu L; Ma ZG
Biomed Environ Sci; 2013 May; 26(5):371-81. PubMed ID: 23611130
[TBL] [Abstract][Full Text] [Related]
29. Inhibiting the mTOR pathway synergistically enhances cytotoxicity in ovarian cancer cells induced by etoposide through upregulation of c-Jun.
Itamochi H; Oishi T; Shimada M; Sato S; Uegaki K; Naniwa J; Sato S; Nonaka M; Terakawa N; Kigawa J; Harada T
Clin Cancer Res; 2011 Jul; 17(14):4742-50. PubMed ID: 21610153
[TBL] [Abstract][Full Text] [Related]
30. Rapamycin restores p14, p15 and p57 expression and inhibits the mTOR/p70S6K pathway in acute lymphoblastic leukemia cells.
Li H; Kong X; Cui G; Ren C; Fan S; Sun L; Zhang Y; Cao R; Li Y; Zhou J
Int J Hematol; 2015 Nov; 102(5):558-68. PubMed ID: 26362858
[TBL] [Abstract][Full Text] [Related]
31. The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models.
Pignochino Y; Dell'Aglio C; Basiricò M; Capozzi F; Soster M; Marchiò S; Bruno S; Gammaitoni L; Sangiolo D; Torchiaro E; D'Ambrosio L; Fagioli F; Ferrari S; Alberghini M; Picci P; Aglietta M; Grignani G
Clin Cancer Res; 2013 Apr; 19(8):2117-31. PubMed ID: 23434734
[TBL] [Abstract][Full Text] [Related]
32. mTOR kinase inhibitors synergize with histone deacetylase inhibitors to kill B-cell acute lymphoblastic leukemia cells.
Beagle BR; Nguyen DM; Mallya S; Tang SS; Lu M; Zeng Z; Konopleva M; Vo TT; Fruman DA
Oncotarget; 2015 Feb; 6(4):2088-100. PubMed ID: 25576920
[TBL] [Abstract][Full Text] [Related]
33. Rapamycin regulates the proliferation of Huh7, a hepatocellular carcinoma cell line, by up-regulating p53 expression.
Kwon S; Jeon JS; Ahn C; Sung JS; Choi I
Biochem Biophys Res Commun; 2016 Oct; 479(1):74-9. PubMed ID: 27616194
[TBL] [Abstract][Full Text] [Related]
34. Growth inhibition and suppression of the mTOR and Wnt/β-catenin pathways in T-acute lymphoblastic leukemia by rapamycin and MYCN depletion.
Kong D; Fan S; Sun L; Chen X; Zhao Y; Zhao L; Guo Z; Li Y
Hematol Oncol; 2021 Apr; 39(2):222-230. PubMed ID: 33300153
[TBL] [Abstract][Full Text] [Related]
35. Essential role for cyclic-AMP responsive element binding protein 1 (CREB) in the survival of acute lymphoblastic leukemia.
van der Sligte NE; Kampen KR; ter Elst A; Scherpen FJ; Meeuwsen-de Boer TG; Guryev V; van Leeuwen FN; Kornblau SM; de Bont ES
Oncotarget; 2015 Jun; 6(17):14970-81. PubMed ID: 26008971
[TBL] [Abstract][Full Text] [Related]
36. Downregulating CREBBP inhibits proliferation and cell cycle progression and induces daunorubicin resistance in leukemia cells.
Gao C; Liu SG; Lu WT; Yue ZX; Zhao XX; Xing TY; Chen ZP; Zheng HY; Li ZG
Mol Med Rep; 2020 Oct; 22(4):2905-2915. PubMed ID: 32945392
[TBL] [Abstract][Full Text] [Related]
37. Idarubicin induces mTOR-dependent cytotoxic autophagy in leukemic cells.
Ristic B; Bosnjak M; Arsikin K; Mircic A; Suzin-Zivkovic V; Bogdanovic A; Perovic V; Martinovic T; Kravic-Stevovic T; Bumbasirevic V; Trajkovic V; Harhaji-Trajkovic L
Exp Cell Res; 2014 Aug; 326(1):90-102. PubMed ID: 24907655
[TBL] [Abstract][Full Text] [Related]
38. The dual kinase inhibitor NVP-BEZ235 in combination with cytotoxic drugs exerts anti-proliferative activity towards acute lymphoblastic leukemia cells.
Schult C; Dahlhaus M; Glass A; Fischer K; Lange S; Freund M; Junghanss C
Anticancer Res; 2012 Feb; 32(2):463-74. PubMed ID: 22287733
[TBL] [Abstract][Full Text] [Related]
39. Expression of the miR-150 tumor suppressor is restored by and synergizes with rapamycin in a human leukemia T-cell line.
Podshivalova K; Wang EA; Hart T; Salomon DR
Leuk Res; 2018 Nov; 74():1-9. PubMed ID: 30269036
[TBL] [Abstract][Full Text] [Related]
40. Silencing profilin-1 inhibits gastric cancer progression via integrin β1/focal adhesion kinase pathway modulation.
Cheng YJ; Zhu ZX; Zhou JS; Hu ZQ; Zhang JP; Cai QP; Wang LH
World J Gastroenterol; 2015 Feb; 21(8):2323-35. PubMed ID: 25741138
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
